#### ATI Physical Therapy Reports Third Quarter 2023 Results

Drove Continued Growth in Visits, Rate per Visit, Revenue and Adjusted EBITDA
Reflecting Continuing Execution of Transformation Initiatives and Strong Demand for Physical Therapy

Robust Therapist Hiring and Retention Results in Growing Clinician Base Advancing Company's Capacity to Expand Patient Access to High-Quality Care

BOLINGBROOK, Ill., Nov. 6, 2023 /PRNewswire/ -- ATI Physical Therapy, Inc. (NYSE: ATIP) ("ATI" or the "Company"), a nationally recognized outpatient physical therapy provider in the United States, today reported financial results for the third quarter ended September 30, 2023.

"We continued growing many key performance metrics in the third quarter," saidSharon Vitti, Chief Executive Officer of ATI. "Despite a constrained labor market in the industry, our ongoing commitment to the ATI culture and our front-line teams resulted in a 5% quarter-over-quarter increase in clinician headcount. We continue to pursue our strategic vision to lead in the musculoskeletal sector while helping people live healthier."

Ms. Vitti added, "Equally exciting, we saw higher rates per visit in the third quarter due to strong rate realization and continuing operational improvements in our revenue cycle management processes. The increase was further augmented by higher rates in new contracts and renewals."

Joe Jordan, Chief Financial Officer of ATI, said, "Our people and operational initiatives are generating solid progress in financial results. As we approach the end of the year, we have increased confidence in the top end of our guidance range."

#### **Third Quarter 2023 Results**

Supplemental tables of key performance metrics for the first quarter of 2021 through the third quarter of 2023 are presented after the financial statements at the end of this press release. Commentary on performance results in the third quarter of 2023 is as follows:

- Net revenue was \$177.5 million compared to \$172.3 million in the second quarter of 2023 and \$156.8 million in the third quarter of 2022, an increase of 3.0% quarter-over-quarter and 13.2% year-over-year. The increases were primarily due to a higher rate per visit, adept execution by the Company's clinicians to ensure access for patients, and strong demand for ATI's physical therapy ("PT") and adjacent services, partially offset by one less business day.
  - Net patient revenue was \$162.3 million compared to \$156.9 million in the second quarter of 2023 and \$142.3 million in the third quarter of 2022, an increase of 3.4% quarter-over-quarter and 14.0% year-over-year. See below for discussion of drivers to net patient revenue (i.e., patient visits and Rate per Visit).
  - Other revenue was \$15.2 million compared to \$15.4 million in the second quarter of 2023 and \$14.5 million in the third quarter
    of 2022, a decrease of 1.3% quarter-over-quarter and an increase of 5.0% year-over-year. The year-over-year increase was
    mostly due to higher MSA revenue.
- Visits per Day ("VPD") were 23,435 compared to 23,412 in the second quarter of 2023 and 21,493 in the third quarter of 2022, an increase of 0.1% quarter-over-quarter and 9.0% year-over-year. The year-over-year increase was driven by the Company's increased capacity to see patients through a higher number of clinical FTE and higher productivity per clinical FTE.
  - VPD per Clinic was 25.9 compared to 25.7 in the second quarter of 2023 and 23.2 in the third quarter of 2022, an increase of 0.2 visits quarter-over-quarter and 2.7 visits year-over-year. These increases were primarily driven by the Company's continued focus on operational excellence within its clinics and ongoing footprint optimization efforts.
- Rate per Visit ("RPV") was \$109.90 compared to \$104.74 in the second quarter of 2023 and \$103.46 in the third quarter of 2022, an increase of 4.9% quarter-over-quarter and 6.2% year-over-year. The increases in RPV were primarily driven by adjustments due to favorable rate realization on prior period visits, operational improvements around front-end and claims submission processes, and favorable contracting in certain key markets.
- Salaries and related costs were \$97.1 million compared to \$95.3 million in the second quarter of 2023 and \$90.3 million in the third quarter of 2022, an increase of 1.8% quarter-over-quarter and 7.5% year-over-year. The quarter-over-quarter increase was primarily due to more clinicians and support staff in addition to higher group health expenses. The year-over-year increase was primarily due to added clinicians and support staff, wage inflation, and bonuses and stock-based awards for our care providers.
- PT salaries and related costs per visit were \$57.47 compared to \$54.81 in the second quarter of 2023 and \$56.20 in the third quarter of 2022, an increase of 4.8% quarter-over-quarter and 2.3% year-over-year. The quarter-over-quarter increase was primarily due to lower labor productivity of 9.3 VPD per clinical FTE compared to 9.5 in the second quarter of 2023, driven by seasonality and integration of new team members. The year-over-year increase was primarily due to a reconfigured clinic support structure and

higher compensation per clinical FTE, partially offset by a higher labor productivity of 9.3 VPD per clinical FTE compared to 8.7 in the third guarter of 2022.

- Rent, clinic supplies, contract labor and other was\$52.7 million compared to \$50.4 million in the second quarter of 2023 and \$51.4 million in the third quarter of 2022, an increase of 4.5% quarter-over-quarter and 2.5% year-over-year. The increases were primarily driven by higher spend on contract labor and outside services.
- PT rent, clinic supplies, contract labor and other per clinic was\$57,012 compared to \$53,866 in the second quarter of 2023 and \$53,945 in the third quarter of 2022, an increase of 5.8% quarter-over-quarter and 5.7% year-over-year. The increases were primarily driven by higher spend on contractor labor and outside services.
- Provision for doubtful accounts was \$3.3 million compared to \$2.4 million in the second quarter of 2023 and \$2.8 million in the third quarter of 2022. PT provision as a percentage of net patient revenue was 2.1% compared to 2.0% in the third quarter of 2022.
- Selling, general and administrative expenses were \$25.1 million compared to \$36.6 million in the second quarter of 2023 and \$25.3 million in the third quarter of 2022, a decrease of 31.4% quarter-over-quarter and 0.7% year-over-year. The quarter-over-quarter decrease was driven primarily by the absence of one-time debt and capital transaction costs incurred in the second quarter of 2023 and insurance reimbursements related to non-ordinary course legal costs. The slight year-over-year decrease was primarily driven by insurance reimbursements for non-ordinary legal costs, mostly offset by higher non-ordinary legal and regulatory costs and employee incentive awards.
- Interest expense during the quarter was\$15.5 million, compared to \$16.7 million in the second quarter of 2023 and \$11.8 million in the third quarter of 2022. The quarter-over-quarter decrease was primarily due to a lower interest rate hedge benefit, and the year-over-year increase was primarily due to higher interest rates and lower interest rate hedge benefit.
- Income tax expense (benefit) was\$0.1 million, compared to\$0.1 million in the second quarter of 2023 and\$(7.2) million in the third quarter of 2022.
- Net loss was \$14.6 million compared to \$21.7 million in the second quarter of 2023 and \$116.7 million in the third quarter of 2022.
- Fully diluted Class A common stock loss per share was\$4.42 compared to \$17.74 in the second quarter of 2023 and \$29.76 in the third quarter of 2022, adjusted on a retrospective basis to reflect the reverse stock split completed in June 2023.
- Adjusted EBITDA<sup>1</sup> was \$9.4 million compared to \$9.3 million in the second quarter of 2023 and \$(0.4) million in the third quarter of 2022. The quarter-over-quarter increase was primarily driven by higher revenue from an increase in rate per visit in addition to lower one-time costs and benefits, mostly offset by higher clinic operating expenses. The year-over-year increase was primarily driven by higher revenue from both more visits and a higher rate per visit, partially offset by higher clinic operating expenses.

Adjusted EBITDA<sup>1</sup> margin was 5.3% compared to 5.4% in the second guarter of 2023 and (0.3)% in the third guarter of 2022.

Net decrease in cash was \$63.4 million year-to-date compared to essentially break-even in the first nine months of 2022.

Operating cash use was \$17.8 million year-to-date compared to \$59.1 million in the first nine months of 2022, reflecting higher earnings in addition to conclusion of the Medicare Accelerated and Advance Payment Program ("MAAPP") repayments in the third quarter of 2022 and other timing differences between accrual and cash basis.

Investing cash use was \$14.6 million year-to-date compared to \$21.9 million in the first nine months of 2022, with the decrease primarily due to fewer new clinic openings. Specifically, 13 clinics were opened year-to-date compared to 33 clinics in the prior comparative period.

Financing cash use was \$31.0 million year-to-date, which included revolver net repayments of \$24.8 million. Financing cash generated was \$80.9 million in the first nine months of 2022, which included refinancing the Company's first lien term loan with a new credit agreement and issuing Series A preferred stock with detachable warrants.

• As of September 30, 2023, total liquidity was \$39.7 million comprised of cash and cash equivalents of \$19.7 million and available revolving credit facility of \$20.0 million. The Company also has access to a \$25.0 million delayed draw term loan.

Additionally, ATI opened three clinics and closed fourteen clinics during the quarter in connection with the Company's ongoing footprint optimization initiative. The Company had 900 clinics at the end of the third quarter.

#### **Third Quarter 2023 Earnings Conference Call**

Management will host a conference call at5 p.m. Eastern Time on November 6, 2023 to review third quarter 2023 financial results. The conference call can be accessed via a live audio webcast. To join, please access the following web link, <u>ATI Physical Therapy, Inc. Q3 2023 Earnings Conference Call</u>, on the Company's Investor Relations website athttps://investors.atipt.com at least 15 minutes early to register and download and install any necessary audio software. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.

<sup>1</sup> Refer to "Non-GAAP Financial Measures" below.

#### **About ATI Physical Therapy**

At ATI Physical Therapy, we are committed to helping people live better. We provide convenient access to high-quality care to prevent and treat musculoskeletal (MSK) pain. Our approximately 900 locations in 24 states and virtual practice operate under the largest single-branded platform built to support standardized clinical guidelines and operating processes. With outcomes from more than 3 million unique patient cases, ATI strives to utilize quality standards designed to deliver proven, predictable, and impactful patient outcomes. From preventative services in the workplace and athletic training support to outpatient clinical services and online physical therapy via our online platform, CONNECT<sup>TM</sup>, a complete list of our service offerings can be found at ATIpt.com. ATI is based in Bolingbrook, Illinois.

#### Forward-Looking Statements

All statements other than statements of historical facts contained in this communication are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of the words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "project," "forecast," "predict," "potential," "seem," "seek," "future," "outlook," "target" or similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding the impact of physical therapist attrition and ability to achieve and maintain clinical staffing levels and clinician productivity, anticipated visit and referral volumes and other factors on the Company's overall profitability, and estimates and forecasts of other financial and performance metrics and projections of market opportunity. These statements are based on various assumptions, whether or not identified in this communication, and on the current expectations of the Company's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of the Company.

These forward-looking statements are subject to a number of risks and uncertainties, including:

- our liquidity position raises substantial doubt about our ability to continue as a going concern;
- risks associated with liquidity and capital markets, including the Company's ability to generate sufficient cash flows, together with cash on hand, to run its business, cover liquidity and capital requirements and resolve substantial doubt about the Company's ability to continue as a going concern;
- our ability to meet financial covenants as required by our 2022 Credit Agreement, as amended;
- risks related to outstanding indebtedness and preferred stock, rising interest rates and potential increases in borrowing costs, compliance with associated covenants and provisions and the potential need to seek additional or alternative debt or capital financing in the future;
- risks related to the Company's ability to access additional financing or alternative options when needed;
- our dependence upon governmental and third-party private payors for reimbursement and that decreases in reimbursement rates, renegotiation or termination of payor contracts, billing disputes with third-party payors or unfavorable changes in payor, state and service mix may adversely affect our financial results;
- federal and state governments' continued efforts to contain growth in Medicaid expenditures, which could adversely affect the Company's revenue and profitability;
- payments that we receive from Medicare and Medicaid being subject to potential retroactive reduction;
- changes in Medicare rules and guidelines and reimbursement or failure of our clinics to maintain their Medicare certification and/or enrollment status;
- compliance with federal and state laws and regulations relating to the privacy of individually identifiable patient information, and associated fines and penalties for failure to comply;
- risks associated with public health crises, including COVID-19 (and any existing and future variants) and its direct and indirect impacts or lingering effects on the business, which could lead to a decline in visit volumes and referrals;
- our inability to compete effectively in a competitive industry, subject to rapid technological change and cost inflation, including competition that could impact the effectiveness of our strategies to improve patient referrals and our ability to identify, recruit, hire and retain skilled physical therapists;
- our inability to maintain high levels of service and patient satisfaction;
- risks associated with the locations of our clinics, including the economies in which we operate, size and expected growth of our addressable markets, and the potential need to close clinics and incur closure costs;
- our dependence upon the cultivation and maintenance of relationships with customers, suppliers, physicians and other referral sources:
- the severity of climate change or the weather and natural disasters that can occur in the regions of the U.S. in which we operate, which could cause disruption to our business:
- risks associated with future acquisitions, divestitures and other business initiatives, which may use significant resources, may be unsuccessful and could expose us to unforeseen liabilities;
- failure of third-party vendors, including customer service, technical and IT support providers and other outsourced professional service providers to adequately address customers' requests and meet Company requirements;
- risks associated with our ability to secure renewals of current suppliers and other material agreements that the Company currently depends upon for business operations;

- risks associated with our reliance on IT infrastructure in critical areas of our operations including, but not limited to, cyber and other security threats:
- a security breach of our IT systems or our third-party vendors' IT systems may subject us to potential legal action and reputational harm and may result in a violation of the Health Insurance Portability and Accountability Act of 1996 or the Health Information Technology for Economic and Clinical Health Act;
- maintaining clients for which we perform management and other services, as a breach or termination of those contractual
  arrangements by such clients could cause operating results to be less than expected;
- our failure to maintain financial controls and processes over billing and collections or disputes with third-party private payors could have a significant negative impact on our financial condition and results of operations;
- our operations are subject to extensive regulation and macroeconomic uncertainty;
- our ability to meet revenue and earnings expectations;
- · risks associated with applicable state laws regarding fee-splitting and professional corporation laws;
- inspections, reviews, audits and investigations under federal and state government programs and third-party private payor contracts that could have adverse findings that may negatively affect our business, including our results of operations, liquidity, financial condition and reputation;
- changes in or our failure to comply with existing federal and state laws or regulations or the inability to comply with new government regulations on a timely basis;
- our ability to maintain necessary insurance coverage at competitive rates;
- the outcome of any legal and regulatory matters, proceedings or investigations instituted against us or any of our directors or
  officers, and whether insurance coverage will be available and/or adequate to cover such matters or proceedings;
- general economic conditions, including but not limited to inflationary and recessionary periods;
- changes in the political environment and events involving financial volatility, defaults or other adverse developments that affect the U.S. or global markets, resulting in liquidity problems which may have a material adverse effect on our results of operations;
- our facilities face competition for experienced physical therapists and other clinical providers that may increase labor costs, result in elevated levels of contract labor and reduce profitability;
- risks associated with our ability to attract and retain talented executives and employees amidst the impact of unfavorable labor market dynamics, wage inflation and recent reduction in value of our share-based compensation incentives, including potential failure of steps being taken to reduce attrition of physical therapists and increase hiring of physical therapists;
- risks resulting from the 2L Notes, IPO Warrants, Earnout Shares and Vesting Shares being accounted for as liabilities at fair value and the changes in fair value affecting our financial results;
- further impairments of goodwill and other intangible assets, which represent a significant portion of our total assets, especially in view of the Company's recent market valuation;
- our inability to remediate the material weaknesses in internal control over financial reporting related to income taxes and to maintain effective internal control over financial reporting;
- risks related to dilution of Common Stock ownership interests and voting interests as a result of the issuance of 2L Notes and Series B Preferred Stock;
- · costs related to operating as a public company; and
- risks associated with our efforts and ability to regain and sustain compliance with the listing requirements of our securities on the New York Stock Exchange ("NYSE").

If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements.

Investors should also review those factors discussed in the Company' Form 10-K for the fiscal year ended ecember 31, 2022, under the heading "Risk Factors," and other documents filed, or to be filed, by ATI with the SEC. New risk factors emerge from time to time and it is not possible to predict all such risk factors, nor can the Company assess the impact of all such risk factors on the business of the Company or the extent to which any factor or combination of factors may cause actual results to differ materially from those contained in any forward-looking statements. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by the foregoing cautionary statements. Readers should not place undue reliance on forward-looking statements. The Company undertakes no obligations to publicly update or revise any forward-looking statements after the date they are made or to reflect the occurrence of unanticipated events, whether as a result of new information, future events or otherwise, except as required by law.

In addition, statements of belief and similar statements reflect the beliefs and opinions of the Company on the relevant subject. These statements are based upon information available to the Company, as applicable, as of the date of this communication, and while the Company believes such information forms a reasonable basis for such statements, such information may be limited or incomplete, and statements should not be read to indicate that the Company has conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and you are cautioned not to unduly rely upon these statements.

#### **Non-GAAP Financial Measures**

To supplement the Company's financial information presented in accordance with GAAP and aid understanding of the Company's business performance, the Company uses certain non-GAAP financial measures, namely "Adjusted EBITDA" and "Adjusted EBITDA margin." ATI believes Adjusted EBITDA and Adjusted EBITDA margin (i.e., Adjusted EBITDA divided by Net Revenue) assist investors and analysts in comparing the Company's operating performance across reporting periods on a consistent basis by excluding items that it does not believe are indicative of ATI's core operating performance.

Management believes these non-GAAP financial measures are useful to investors in highlighting trends in our operating performance, while other measures can differ significantly depending on long-term strategic decisions regarding capital structure, the tax jurisdictions in

which ATI operates and capital investments. Management uses these non-GAAP financial measures to supplement GAAP measures of performance in the evaluation of the effectiveness of the Company's business strategies, to make budgeting decisions, to establish discretionary annual incentive compensation and to compare ATI's performance against that of other peer companies using similar measures. Management supplements GAAP results with non-GAAP financial measures to provide a more complete understanding of the factors and trends affecting the business than GAAP results alone.

Adjusted EBITDA and Adjusted EBITDA margin are not recognized terms under GAAP and should not be considered as an alternative to net income (loss) or the ratio of net income (loss) to net revenue as a measure of financial performance, cash flows provided by operating activities as a measure of liquidity, or any other performance measure derived in accordance with GAAP. Additionally, these measures are not intended to be a measure of cash available for management's discretionary use as they do not consider certain cash requirements such as interest payments, tax payments and debt service requirements. The presentations of these measures have limitations as analytical tools and should not be considered in isolation, or as a substitute for analysis of the Company's results as reported under GAAP. Because not all companies use identical calculations, the presentations of these measures may not be comparable to other similarly titled measures of other companies and can differ significantly from company to company.

Please see "Reconciliation of GAAP to Non-GAAP Financial Measures" below for reconciliations of non-GAAP financial measures used in this release to their most directly comparable GAAP financial measures. We are unable to provide a reconciliation between forward-looking Adjusted EBITDA to its comparable GAAP financial measure without unreasonable effort, due to the high difficulty and impracticability of predicting certain amounts required by GAAP with a reasonable degree of accuracy by the date of this release.

#### Contacts:

Investors
Joanne Fong
SVP, Treasurer and Investor Relations
ATI Physical Therapy
investors@atipt.com
(630) 296-2222 x 7131

Media Genesa Garbarino Garbo Communications genesa@garbo.agency 424-499-7025

Rob Manker
Director of Marketing & Public Relations
ATI Physical Therapy
warren.manker@atipt.com
630-296-2222 ext. 7432

# ATI Physical Therapy Condensed Consolidated Statements of Operations (\$ in thousands)

(\$ in thousands) (unaudited)

	Three Mor	nths E	inded	Nine Months Ended				
	eptember 80, 2023	September 30, 2022		September 30, 2023		September 30, 2022		
Net patient revenue	\$ 162,258	\$	142,313	\$	469,950	\$	429,744	
Other revenue	15,197		14,479		46,774		44,163	
Net revenue	177,455		156,792		516,724		473,907	
Cost of services:								
Salaries and related costs	97,089		90,309		283,119		267,330	
Rent, clinic supplies, contract labor and other	52,699		51,417		156,014		153,437	
Provision for doubtful accounts	3,346		2,797		9,831		11,408	
Total cost of services	 153,134		144,523		448,964	_	432,175	
Selling, general and administrative expenses	25,085		25,263		92,253		87,095	
Goodwill, intangible and other asset impairment charges	_		106,663		_		390,224	
Operating loss	 (764)		(119,657)		(24,493)	_	(435,587)	
Change in fair value of 2L Notes	(1,485)		_		(8,495)		_	
Change in fair value of warrant liability	(88)		(790)		(88)		(3,651)	
Change in fair value of contingent common shares liability	(306)		(6,930)		(1,807)		(32,760)	
Interest expense, net	15,478		11,780		46,096		31,815	

Other expense, net		117	195	1,089	3,181
Loss before taxes		(14,480)	(123,912)	(61,288)	(434,172)
Income tax expense (benefit)		131	(7,218)	282	(43,532)
Net loss		(14,611)	(116,694)	(61,570)	(390,640)
Net income (loss) attributable to non-controlling interests		586	(376)	2,602	(1,026)
Net loss attributable to ATI Physical Therapy, Inc.		(15,197)	(116,318)	(64,172)	(389,614)
Less: Series A Senior Preferred Stock redemption value adjustments	3	(2,927)	_	41,769	
Less: Series A Senior Preferred Stock cumulative dividend		6,075	5,274	17,087	12,263
Net loss available to common stockholders	\$	(18,345)	\$ (121,592)	\$ (123,028)	\$ (401,877)
Loss per share of Class A common stock:					
Basic	\$	(4.42)	\$ (29.76)	\$ (29.83)	\$ (99.13)
Diluted	\$	(4.42)	\$ (29.76)	\$ (29.83)	\$ (99.13)
Weighted average shares outstanding:					
Basic and diluted		4,154	4,086	4,125	4,054

# ATI Physical Therapy Condensed Consolidated Balance Sheets (\$ in thousands) (unaudited)

	Septem	nber 30, 2023	Decen	nber 31, 2022
Assets:	-			
Current assets:				
Cash and cash equivalents	\$	19,730	\$	83,139
Accounts receivable (net of allowance for doubtful accounts of \$50,789 and				
\$47,620 at September 30, 2023 and December 31, 2022, respectively)		84,970		80,673
Prepaid expenses		12,458		13,526
Other current assets		6,367		10,040
Assets held for sale				6,755
Total current assets		123,525		194,133
Property and equipment, net		109,652		123,690
Operating lease right-of-use assets		207,802		226,092
Goodwill, net		289,650		286,458
Trade name and other intangible assets, net		246,028		246,582
Other non-current assets		1,866		2,030
Total assets	\$	978,523	\$	1,078,985
Liabilities, Mezzanine Equity and Stockholders' Equity:				
Current liabilities:				
Accounts payable	\$	11,456	\$	12,559
Accrued expenses and other liabilities		55,618		53,672
Current portion of operating lease liabilities		52,351		47,676
Liabilities held for sale				2,614
Total current liabilities		119,425		116,521
Long-term debt, net <sup>(1)</sup>		417,379		531,600
2L Notes due to related parties, at fair value		95,448		· —
Warrant liability		10		98
Contingent common shares liability		1,028		2,835
Deferred income tax liabilities		19,168		18,886
Operating lease liabilities		197,084		218,424
Other non-current liabilities		1,654		1,834
Total liabilities	-	851,196		890,198
Commitments and contingencies				
Mezzanine equity:				

217,072 140,340

<sup>(1)</sup> Includes \$16.9 million of principal amount of debt due to related parties as of September 30, 2023.

#### Stockholders' equity:

<u>2</u> 1	
_	_
(217)	(146)
1,309,166	1,378,716
550	4,899
(1,403,683)	(1,339,511)
(94,184)	43,958
4,439	4,489
(89,745)	48,447
\$ 978,523	\$ 1,078,985
	(217) 1,309,166 550 (1,403,683) (94,184) 4,439 (89,745)

#### ATI Physical Therapy Condensed Consolidated Statements of Cash Flows

(\$ in thousands) (unaudited)

	Nine Months Ended				
	Sep	tember 30, 2023	Se	otember 30, 2022	
Operating activities:					
Net loss	\$	(61,570)	\$	(390,640)	
Adjustments to reconcile net loss to net cash used in operating activities:					
Goodwill, intangible and other asset impairment charges		_		390,224	
Depreciation and amortization		28,341		30,477	
Provision for doubtful accounts		9,831		11,408	
Deferred income tax provision		282		(43,532)	
Non-cash lease expense related to right-of-use assets		35,844		36,155	
Non-cash share-based compensation		6,492		5,830	
Amortization of debt issuance costs and original issue discount		2,200		1,934	
Non-cash interest expense		6,020		889	
Loss on extinguishment of debt		444		2,809	
Loss (gain) on disposal and sale of assets		1,519		(42)	
Change in fair value of 2L Notes		(8,495)		_	
Change in fair value of warrant liability		(88)		(3,651)	
Change in fair value of contingent common shares liability		(1,807)		(32,760)	
Change in fair value of non-designated derivative instrument		(67)		_	
Changes in:					
Accounts receivable, net		(13,642)		(11,276)	
Prepaid expenses and other current assets		(549)		(5,507)	
Other non-current assets		94		52	
Accounts payable		(1,109)		(2,100)	
Accrued expenses and other liabilities		9,015		(702)	
Operating lease liabilities		(34,694)		(36,431)	
Other non-current liabilities		73		52	
Medicare Accelerated and Advance Payment Program Funds		_		(12,269)	
Proceeds from legal cost insurance reimbursements		4,091		_	
Net cash used in operating activities		(17,775)		(59,080)	
Investing activities:					
Purchases of property and equipment		(14,592)		(22,091)	
Proceeds from sale of property and equipment		91		152	

Proceeds from sale of clinics		355		77
Payment of holdback liabilities related to acquisitions		(490)		
Net cash used in investing activities		(14,636)		(21,862)
The case with the case of the		(1.,000)		(=:,00=)
Financing activities:				
Proceeds from long-term debt		_		500,000
Proceeds from 2L Notes from related parties		3,243		_
Financing transaction costs		(6,287)		_
Deferred financing costs		(84)		(12,952)
Original issue discount		_		(10,000)
Principal payments on long-term debt		_		(555,048)
Proceeds from issuance of Series A Senior Preferred Stock		_		144,667
Proceeds from issuance of 2022 Warrants		_		20,333
Proceeds from revolving line of credit		20,000		_
Payments on revolving line of credit		(44,750)		_
Equity issuance costs and original issue discount		_		(4,935)
Payment of contingent consideration liabilities		(397)		_
Taxes paid on behalf of employees for shares withheld		(71)		(41)
Distribution to non-controlling interest holders		(2,652)		(1,129)
Net cash (used in) provided by financing activities	-	(30,998)		80,895
Changes in cash and cash equivalents:				
Net decrease in cash and cash equivalents		(63,409)		(47)
Cash and cash equivalents at beginning of period		83,139		48,616
Cash and cash equivalents at end of period	\$	19,730	\$	48,569
Cumplemental manageh disalaguwan				
Supplemental noncash disclosures:				
Derivative changes in fair value <sup>(1)</sup>	\$	4,349	\$	(7,115)
Purchases of property and equipment in accounts payable	\$	1,644	\$	2,230
Exchange of Senior Secured Term Loan for related party 2L Notes	\$	100,000	\$	_
Debt discount on Senior Secured Term Loan	\$	(1,797)	\$	_
Capital contribution from recognition of delayed draw right asset	\$	690	\$	_
Series A Senior Preferred Stock dividends and redemption value adjustments	\$\$	76,732	\$	_
Other supplemental disclosures:				
Cash paid for interest	\$	38,998	\$	29,453
Cash received from hedging activities	\$	5,247	\$	1,080
Cash paid for taxes	\$	1	\$	82
•	•		•	-

<sup>&</sup>lt;sup>(1)</sup> Derivative changes in fair value related to unrealized loss (gain) on cash flow hedges, including the impact of reclassifications.

## ATI Physical Therapy, Inc. Supplemental Tables of Key Performance Metrics

Financial Metrics (\$ in 000's)

		-		(+	,
	Net Patient	Other		Adjusted	Adj EBITDA
	Revenue	Revenue	Net Revenue	EBITDA	margin
Q1 2021	\$132,271	\$16,791	\$149,062	\$5,590	3.8 %
Q2 2021	\$146,679	\$17,354	\$164,033	\$23,999	14.6 %
Q3 2021	\$141,855	\$17,158	\$159,013	\$8,539	5.4 %
Q4 2021	\$140,275	\$15,488	\$155,763	\$1,643	1.1 %
Q1 2022	\$138,925	\$14,897	\$153,822	\$(4,695)	(3.1) %
Q2 2022	\$148,506	\$14,787	\$163,293	\$5,436	3.3 %
Q3 2022	\$142,313	\$14,479	\$156,792	\$(392)	(0.3) %
Q4 2022	\$146,196	\$15,568	\$161,764	\$6,363	3.9 %
Q1 2023	\$150,754	\$16,178	\$166,932	\$4,790	2.9 %
Q2 2023	\$156,938	\$15,399	\$172,337	\$9,338	5.4 %
Q3 2023	\$162,258	\$15,197	\$177,455	\$9,429	5.3 %

#### **Operational Metrics**

	operational method									
	Visits Clinical		VPD	VPD ATI Clinician		ATI Clinic	ian Headcount			
	per Day (1)	FTE <sup>(2)</sup>	per cFTE (3)	Headcount (4)	Headcount (5)	Adds (6)	Turnover (7)			
Q1 2021	19,520	2,284	8.5	2,558	16	41 %	31 %			
Q2 2021	21,569	2,325	9.3	2,526	43	37 %	44 %			
Q3 2021	20,674	2,359	8.8	2,583	108	51 %	42 %			
Q4 2021	20,649	2,490	8.3	2,650	109	37 %	31 %			
Q1 2022	21,062	2,466	8.5	2,658	158	25 %	23 %			
Q2 2022	22,403	2,465	9.1	2,647	151	26 %	28 %			
Q3 2022	21,493	2,465	8.7	2,691	151	33 %	25 %			
Q4 2022	22,316	2,476	9.0	2,662	123	19 %	26 %			
Q1 2023	22,701	2,423	9.4	2,629	168	21 %	27 %			
Q2 2023	23,412	2,452	9.5	2,681	185	27 %	19 %			
Q3 2023	23,435	2,524	9.3	2,786	214	35 %	20 %			

- (1) Equals patient visits divided by operating days.
- (2) Represents clinical staff hours divided by 8 hours divided by number of paid days.
- (3) Equals patient visits divided by operating days divided by clinical full-time equivalent employees.
- (4) Represents ATI employee clinician headcount at end of period.
- (5) Represents contractor clinician headcount at end of period.
- (6) Represents ATI employee clinician headcount new hire adds divided by average headcount, multiplied by 4 to annualize.
- (7) Represents ATI employee clinician headcount separations divided by average headcount, multiplied by 4 to annualize.

#### **Unit Economics: PT Clinics (\$ actual)**

					( +	,	
-						PT Rent	PT Provision
	Ending	PT Revenue	VPD	PT Rate	PT Salaries	and Other	as % PT
	Clinic Count	per Clinic (1)	per Clinic (2)	per Visit (3)	per Visit <sup>(4)</sup>	per Clinic (5)	Revenue (6)
Q1 2021	882	\$150,536	22.2	\$107.56	\$54.14	\$47,722	5.4 %
Q2 2021	889	\$165,241	24.3	\$106.26	\$48.22	\$47,857	2.4 %
Q3 2021	900	\$158,556	23.1	\$105.56	\$53.70	\$49,499	2.5 %
Q4 2021	910	\$154,772	22.8	\$104.51	\$55.73	\$50,976	1.5 %
Q1 2022	922	\$151,225	22.9	\$103.06	\$55.47	\$54,472	3.7 %
Q2 2022	926	\$160,431	24.2	\$103.57	\$53.64	\$53,017	2.4 %
Q3 2022	929	\$153,410	23.2	\$103.46	\$56.20	\$53,945	2.0 %
Q4 2022	923	\$157,993	24.1	\$103.99	\$54.92	\$51,252	1.7 %
Q1 2023	909	\$165,846	25.0	\$103.76	\$52.98	\$56,338	2.7 %
Q2 2023	911	\$172,207	25.7	\$104.74	\$54.81	\$53,866	1.5 %
Q3 2023	900	\$179,224	25.9	\$109.90	\$57.47	\$57,012	2.1 %

- (1) Equals Net Patient Revenue divided by average clinics over the quarter.
- (2) Equals patient visits divided by operating days divided by average clinics over the quarter
- (3) Equals Net Patient Revenue divided by patient visits.
- (4) Equals estimated patient-related portion of Salaries and Related Costs divided by patient visits.
- (5) Equals estimated patient-related portion of Rent, Clinic Supplies, Contract Labor and Other divided by average clinics over the quarter
- (6) Equals estimated patient-related portion of Provision for Doubtful Accounts divided by Net Patient Revenue.

#### **Customer Satisfaction Metrics**

	Net Promoter	Google Star
	Score (1)	Rating <sup>(2)</sup>
Q1 2021	75	4.9
Q2 2021	77	4.9
Q3 2021	73	4.9
Q4 2021	78	4.8
Q1 2022	74	4.9
Q2 2022	75	4.9
Q3 2022	76	4.8
Q4 2022	76	4.9
Q1 2023	76	4.8
Q2 2023	74	4.8

4.9

75

- (1) NPS measures customer experience from ATI patient survey responses. The score is calculated as the percentage of promoters less the percentage of detractors.
- (2) A Google Star rating is a five-star rating scale that ranks businesses based on customer reviews. Customers are given the opportunity to leave a business review after interacting with a business, which involves choosing from one star (poor) to five stars (excellent).

### ATI Physical Therapy, Inc. Reconciliation of GAAP to Non-GAAP Financial Measures

(\$ in thousands) (unaudited)

	Three Months Ended										
	Sep	tember 30,		June 30,		March 31,					
		2023		2023	2023						
Net loss	\$	(14,611)	\$	(21,749)	\$	(25,210)					
Plus (minus):											
Net income attributable to non-controlling interests		(586)		(956)		(1,060)					
Interest expense, net		15,478		16,682		13,936					
Income tax expense		131		89		62					
Depreciation and amortization expense		9,154		9,211		9,564					
EBITDA	\$	9,566	\$	3,277	\$	(2,708)					
Change in fair value of 2L Notes <sup>(1)</sup>		(1,485)		(7,010)		_					
Changes in fair value of warrant liability and contingent commo	n										
shares liability <sup>(2)</sup>		(394)		(990)		(511)					
Legal cost insurance reimbursements (3)		(4,274)		_		_					
Non-ordinary legal and regulatory matters (4)		3,559		2,001		1,523					
Share-based compensation		2,286		2,755		1,478					
Transaction and integration costs (5)		215		8,714		5,408					
Change in fair value of non-designated derivative instrument		(67)		_		_					
Pre-opening de novo costs (6)		23		147		172					
Loss on debt extinguishment (7)		_		444		_					
Business optimization costs (8)		_		_		(702)					
Reorganization and severance costs (9)		_		_		130					
Adjusted EBITDA	\$	9,429	\$	9,338	\$	4,790					
Adjusted EBITDA margin		5.3 %	)	5.4 %		2.9 %					

- (1) Represents non-cash amounts related to the change in the estimated fair value of the 2L Notes.
- (2) Represents non-cash amounts related to the change in the estimated fair value of IPO Warrants, Earnout Shares and Vesting Shares.
- (3) Represents insurance reimbursements for legal costs incurred related to the previously disclosed ATIP stockholder class action complaints and derivative complaint.
- (4) Represents non-ordinary course legal costs related to the previously disclosed ATIP stockholder class action complaints, derivative complaint, and SEC matter.
- (5) Represents non-capitalizable debt and capital transaction costs.
- (6) Represents expenses associated with renovation, equipment and marketing costs relating to the start-up and launch of new locations incurred prior to opening.
- (7) Represents charges related to the loss on debt extinguishment recognized as part of the 2023 Debt Restructuring.
- (8) Represents realized benefit of labor related CARES Act credit, that was not previously considered probable and relates to prior years.
- (9) Represents severance costs related to discrete initiatives focused on reorganization and delayering of the Company's labor model, management structure and support functions.

(\$ in thousands) (unaudited)

	Three Months Ended							
	De	ecember 31,	Se	ptember 30,		June 30,	ı	March 31,
		2022		2022		2022		2022
Net loss	\$	(102,407)	\$	(116,694)	\$	(135,723)	\$	(138,223)
Plus (minus):								
Net (income) loss attributable to non-controlling								
interests		(358)		376		177		473
Interest expense, net		13,463		11,780		11,379		8,656
Income tax benefit		(4,998)		(7,218)		(13,033)		(23,281)
Depreciation and amortization expense		9,979		9,907		10,055		9,900
EBITDA	\$	(84,321)	\$	(101,849)	\$	(127,145)	\$	(142,475)
Goodwill, intangible and other asset impairment								
charges <sup>(1)</sup>		96,038		106,663		127,820		155,741
Goodwill, intangible and other asset impairment								
charges attributable to non-controlling interests (1)		(364)		(457)		(654)		(940)
Changes in fair value of warrant liability and								
contingent common shares liability (2)		(10,357)		(7,720)		(2,680)		(26,011)
Loss on debt extinguishment (3)		_		_		_		2,809
Loss on legal settlement (4)		_		_		3,000		_
Share-based compensation		1,544		1,920		2,004		1,964
Non-ordinary legal and regulatory matters (5)		937		772		2,202		2,497
Pre-opening de novo costs (6)		101		224		286		381
Transaction and integration costs (7)		1,093		55		603		1,538
Reorganization and severance costs (8)		1,797		_		_		_
Business optimization costs (9)		(105)		_		_		_
Gain on sale of Home Health service line, net		_		_		_		(199)
Adjusted EBITDA	\$	6,363	\$	(392)	\$	5,436	\$	(4,695)
Adjusted EBITDA margin		3.9 %	,	(0.3) %		3.3 %		(3.1) %

- (1) Represents non-cash charges related to the write-down of goodwill, trade name indefinite-lived intangible and other assets.
- (2) Represents non-cash amounts related to the change in the estimated fair value of IPO Warrants, Earnout Shares and Vesting Shares.
- (3) Represents charges related to the derecognition of the unamortized deferred financing costs and original issuance discount associated with the full repayment of the 2016 first lien term loan.
- (4) Represents charge for net settlement liability related to billing dispute.
- (5) Represents non-ordinary course legal costs related to the previously disclosed ATIP stockholder class action complaints, derivative complaint, and SEC matter.
- (6) Represents expenses associated with renovation, equipment and marketing costs relating to the start-up and launch of new locations incurred prior to opening.
- (7) Represents costs related to the Business Combination with FVAC II and non-capitalizable debt and capital transaction costs.
- (8) Represents severance, consulting and other costs related to discrete initiatives focused on reorganization and delayering of the Company's labor model, management structure and support functions.
- (9) Represents non-recurring costs to optimize our platform and ATI transformative initiatives. Costs primarily relate to duplicate costs driven by IT and Revenue Cycle Management conversions, labor related costs during the transition of key positions and other incremental costs of driving optimization initiatives.

## ATI Physical Therapy, Inc. Reconciliation of GAAP to Non-GAAP Financial Measures

(\$ in thousands) (unaudited)

Three Months Ended

	Tiffee Months Ended								
Net income (loss)	December 31, 2021		September 30, 2021		June 30, 2021		March 31, 2021		
	\$	1,690	\$	(326,774)	\$	(439,126)	\$	(17,818)	
Plus (minus):									
Net (income) loss attributable to non-controlling interests		(869)		2,109		3,769		(1,309)	
Interest expense, net		7,215		7,386		15,632		16,087	

Interest expense on redeemable preferred stock Income tax benefit	— (5,381)	(35,333)	4,779 (19,731)	5,308 (10,515)
Depreciation and amortization expense	10,005	9,222	9,149	9,619
EBITDA	\$ 12,660	\$ (343,390)	\$ (425,528)	\$ 1,372
Goodwill, intangible and other asset impairment				
charges <sup>(1)</sup>	_	508,972	453,331	_
Goodwill, intangible and other asset impairment				
charges attributable to non-controlling interest <sup>(1)</sup>	_	(2,928)	(5,021)	_
Changes in fair value of warrant liability and				
contingent common shares liability (2)	(10,046)	(162,202)	(25,487)	_
Gain on sale of Home Health service line, net	(5,846)	_	_	_
Reorganization and severance costs (3)	_	3,551	_	362
Transaction and integration costs (4)	955	2,335	3,580	2,918
Share-based compensation	905	1,248	3,112	504
Pre-opening de novo costs (5)	543	511	441	434
Non-ordinary legal and regulatory matters (6)	2,472	442	_	_
Loss on debt extinguishment (7)	_	_	5,534	_
Loss on settlement of redeemable preferred stock (8)	_	_	14,037	_
Adjusted EBITDA	\$ 1,643	\$ 8,539	\$ 23,999	\$ 5,590
Adjusted EBITDA margin	1.1 %	5.4 %	14.6 %	3.8 %

- (1) Represents non-cash charges related to the write-down of goodwill, trade name indefinite-lived intangible and other assets.
- (2) Represents non-cash amounts related to the change in the estimated fair value of IPO Warrants, Earnout Shares and Vesting Shares.
- (3) Represents severance, consulting and other costs related to discrete initiatives focused on reorganization and delayering of the Company's labor model, management structure and support functions.
- (4) Represents costs related to the Business Combination with FVAC II, non-capitalizable debt transaction costs, clinic acquisitions and acquisition-related integration and consulting and planning costs related to preparation to operate as a public company.
- (5) Represents expenses associated with renovation, equipment and marketing costs relating to the start-up and launch of new locations incurred prior to opening.
- (6) Represents non-ordinary course legal costs related to the previously disclosed ATIP stockholder class action complaints, derivative complaint, and SEC matter.
- (7) Represents charges related to the derecognition of the proportionate amount of remaining unamortized deferred financing costs and original issuance discount associated with the partial repayment of the first lien term loan and derecognition of the unamortized original issuance discount associated with the full repayment of the subordinated second lien term loan.
- (8) Represents loss on settlement of redeemable preferred stock based on the value of cash and equity provided to preferred stockholders in relation to the outstanding redeemable preferred stock liability at the time of the closing of the Business Combination with FVAC II.

#### SOURCE ATI Physical Therapy

Additional assets available online: Additional assets available online:

https://news.atipt.com/2023-11-06-ATI-Physical-Therapy-Reports-Third-Quarter-2023-Results